Meeting
2018 Gastrointestinal Cancers Symposium
Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) ± 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1.
Authors
Andrea Wang-Gillam
Washington University School of Medicine in St. Louis, St. Louis, MO
Andrea Wang-Gillam , Richard Hubner , Beloo Mirakhur , Floris A de Jong , Bruce Belanger , Li-Tzong Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01494506
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 459)
DOI
10.1200/JCO.2018.36.4_suppl.459
Abstract #
459
Poster Bd #
M6
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A randomized phase II study of second-line treatment with liposomal irinotecan, and S-1 versus liposomal irinotecan and 5-fluorouracil in gemcitabine-refractory metastatic pancreatic cancer patients.
First Author: Esther Pijnappel
Poster
2018 Gastrointestinal Cancers Symposium
Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1: A phase III study of liposomal irinotecan (nal IRI)±5-fluorouracil/ leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy.
First Author: Teresa Mercade Macarulla
Poster
2018 Gastrointestinal Cancers Symposium
Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI‑1: A phase III study of liposomal irinotecan (nal‑IRI)±5‑fluorouracil/leucovorin (5‑FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy.
First Author: Jens T. Siveke
Poster
2018 Gastrointestinal Cancers Symposium
Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal‑IRI)±5‑fluorouracil/leucovorin (5‑FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based (gem) therapy.
First Author: Teresa Mercade Macarulla